Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nathalie Oudry"'
Autor:
Ulrich Burger, Kamel Besseghir, K. Schwach-Abdellaoui, Damien Jeannerat, Robert Gurny, Alexandra Rothen-Weinhold, Séverine Frutiger-Hughes, Nathalie Oudry, Graham J. Hughes
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 49, No 3 (2000) pp. 253-257
Most peptides are susceptible, in vivo, to proteolytic degradation, and it is difficult to formulate and to deliver them without loss of biological activity. In addition, it is often desirable to release them continuously and at a controlled rate ove
Autor:
Robert Gurny, Alexandra Rothen-Weinhold, Emmanuelle Sublet, Kamel Besseghir, E. Vuaridel, Nathalie Oudry
Publikováno v:
International Journal of Pharmaceutics, Vol. 178, No 2 (1999) pp. 213-221
In recent years, peptides and proteins have received much attention as drug candidates. For many polypeptides, particularly hormones, it is desirable to release the drug continuously at a controlled rate over a period of weeks or even months, and thu
Autor:
Gérard Hopfgartner, Emmanuel Varesio, Wei Wang, Nathalie Oudry, Ildiko Szanto, Tatjana Sajic, Joël Iff, Estelle Gueneau
Publikováno v:
Journal of Proteome Research, Vol. 8, No 10 (2009) pp. 4511-24
Increased inflammatory signaling is a key feature of metabolic disorders. In this context, the role of increased pro-inflammatory signals has been extensively studied. By contrast, no efforts have been dedicated to study the contrasting scenario: the
Autor:
Hans Lindner, Pierre Broqua, Jean-Pierre Giliberto, Nathalie Oudry, Grégoire Schwach, Robert Gurny, Martin Lück
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 57, No 3 (2004) pp. 441-6
Poly (DL-lactide-co-glycolide) microparticles (MP) containing a highly potent peptidic gonadotropin releasing hormone antagonist (degarelix) of interest in the prostate cancer indication were screened for biological performance. Efficacy was tested i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2255affafda6355d68a6e1018c6693e
https://archive-ouverte.unige.ch/unige:55312
https://archive-ouverte.unige.ch/unige:55312
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 56, No 3 (2003) pp. 327-336
The formulation of a new GnRH antagonist (degarelix) in biodegradable poly(DL-lactide-co-glycolide) (PLGA) microparticles was investigated for the development of a 3-month sustained release formulation to treat prostate cancer. The aim was to screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128a4a6185f76abc0bd27ee0211c7fd3
https://archive-ouverte.unige.ch/unige:84848
https://archive-ouverte.unige.ch/unige:84848
Autor:
Emmanuelle Sublet, Robert Gurny, Kamel Besseghir, Alexandra Rothen-Weinhold, Nathalie Oudry, E. Vuaridel, Frank Kubel
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 48, No 2 (1999) pp. 113-121
Polylactic acid (PLA) is a biocompatible and biodegradable material with wide utility for many applications, including the design of controlled-release systems for pharmaceutical agents. The factors determining the degradation kinetics of these syste
Autor:
Joël Iff, Wei Wang, Tatjana Sajic, Nathalie Oudry, Estelle Gueneau, Gérard Hopfgartner, Emmanuel Varesio, Ildiko Szanto
Publikováno v:
Journal of Proteome Research; Oct2009, Vol. 8 Issue 10, p4511-4524, 14p